Trulicity

dulaglutide
GLP-1 Receptor Agonist Eli Lilly FDA Monitored

Safety Profile Overview

Once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular benefit in the REWIND trial.

Generic Name
dulaglutide
Brand Names
Trulicity
Therapeutic Class
GLP-1 Receptor Agonist
Manufacturer
Eli Lilly

What Pharma Signal Tracks for Trulicity

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Trulicity Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Trulicity.

curl "https://api.pharma-signal.com/drug/safety/trulicity" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Trulicity against other GLP-1 Receptor Agonist drugs, or explore the full manufacturer portfolio for Eli Lilly.